scout
|Videos|December 14, 2017

Phase III Results for Rucaparib in Ovarian Cancer

Jonathan Ledermann, MD, professor of medical oncology, UCL Cancer Institute, London, United Kingdom, discusses phase III results of a study of rucaparib versus placebo following response to platinum-based chemotherapy for recurrent ovarian cancer.

Newsletter

Stay up to date on practice-changing data in community practice.


Latest CME